BrightPath Biotherapeutics Co (TSE:4594) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4594 BrightPath Biotherapeutics Co Ltd TSE:4594
47 GF Score
Price 円50.00
GF Value 円4.57
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is BrightPath Biotherapeutics Co Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TSE:4594
47GF Score
BrightPath Biotherapeutics Co Ltd TSE:4594
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?

Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued. The current stock price of 円50.00 is trading 994.1% above its estimated GF Value™ of 円4.57. GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.

Key valuation signals for TSE:4594:

  • Short Ratio:
  • GF Value™: 円4.57 vs. price of 円50.00 (994.1% above fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BrightPath Biotherapeutics Co Business Description

Address 2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
47GF Score

Get the complete analysis for TSE:4594

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円50.00
Price
円4.57
GF Value